Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma has received a Certificate of Patent from the Japanese Patent Office (JPO) for its drug candidate LP-284, developed using the company's RADR® AI platform. LP-284, aimed at treating relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas, is currently in a Phase 1 clinical trial. Japan is the third country to issue this patent, following the US in April 2023, with anticipated patents in Europe, China, and other countries. Lantern estimates LP-284 could benefit 40,000 to 80,000 blood cancer patients annually, potentially capturing a $4 billion global market. The drug has also received Orphan Drug Designation from the U.S. FDA for the treatment of high-grade B-cell lymphomas and mantle cell lymphoma.
- Lantern Pharma received a Certificate of Patent from the Japanese Patent Office for LP-284.
- LP-284 is in Phase 1 clinical trial for relapsed/refractory non-Hodgkin’s lymphoma and certain sarcomas.
- Japan is the third country to grant a patent for LP-284, following the US in April 2023.
- Potential global market for LP-284 is estimated at $4 billion annually.
- LP-284 could improve outcomes for 40,000 to 80,000 blood cancer patients annually.
- LP-284 has received Orphan Drug Designation from the U.S. FDA for certain lymphomas.
- FDA has cleared an IND application for LP-284, with first patients dosed in Phase 1 trial.
- LP-284 is still in Phase 1 clinical trials, indicating it is far from market approval.
- The success of LP-284 is uncertain, as clinical trials may not yield positive results.
- Significant financial resources will be required to advance LP-284 through further clinical stages.
- Lantern Pharma's reliance on AI-developed drugs carries inherent risks if the technology does not perform as expected.
The issuance of the patent from the Japanese Patent Office for LP-284 is significant as it strengthens the intellectual property (IP) position of Lantern Pharma. A composition of matter patent is particularly valuable because it covers the actual chemical structure of the molecule, offering the highest level of protection against generic competitors. This patent, along with similar patents in the US and potentially other major markets, creates a robust IP portfolio that could facilitate licensing deals, partnerships and potentially lucrative market exclusivity. The patent's expiry in 2039 provides a long runway for commercial exploitation, which is beneficial for Lantern Pharma's long-term strategic plans.
For investors, strong IP protection can translate to market confidence, potentially leading to stock price appreciation and improved negotiating power for the company in global markets.
The clinical implications of LP-284 are noteworthy, given its potential to address relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL). These are areas with significant unmet medical needs, as nearly all patients diagnosed with MCL relapse after treatment. The current market potential, estimated at $4 billion annually, underscores the substantial demand for more effective therapies.
The use of Lantern’s AI platform, RADR®, in developing LP-284 is also a key point. This platform optimizes the drug development process, potentially accelerating timelines and enhancing the precision of therapeutic targets. For retail investors, the AI-driven approach can be seen as a modern and efficient method in drug development, which may reduce costs and increase the likelihood of clinical success.
From a financial perspective, this news is quite positive for Lantern Pharma. The patent increases the potential for future revenue streams by protecting the molecule from generic competition in Japan, a significant market. The estimated market potential for LP-284 in blood cancers at $4 billion globally is substantial. Additionally, the patent could enhance Lantern’s ability to attract strategic partnerships or investors, further solidifying its financial standing.
Lantern Pharma's strategy to secure patents in multiple regions, including the US, Europe, China and others, is a prudent approach to maximizing global market opportunities. This adds a layer of security for long-term investors, given the extended period of market exclusivity up to 2039.
- LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas.
- LP-284 is the third molecule brought to clinical trials by Lantern Pharma using insights and support from RADR®, Lantern’s AI, machine learning and computational biology platform focused on oncology drug development.
-
Japan is the third country to date where a composition of matter patent has been issued for LP-284. - The addition of the new patent further strengthens LP-284’s future clinical development and creates pathways for potential future geographic partnerships.
-
Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of
$4 Billion USD
“The addition of a JPO-issued patent for LP-284 to our intellectual property portfolio strengthens the future of this novel therapeutic for the commercial market and expands the potential for LP-284 to positively impact outcomes for patients with unmet needs in non-Hodgkin’s lymphomas,” said Panna Sharma, CEO and President, Lantern Pharma. “It also supports the use of Lantern’s AI technologies to accelerate the development of novel cancer therapies.”
Lantern previously received a similar patent on LP-284 from the US Patent and Trademark Office (USPTO) in April 2023, with an expiry in early 2039. Lantern anticipates receiving similar or same patent rights for LP-284 in
LP-284 has already seen significant success in its progress in
MCL accounts for up to ~5,800 cases of NHL in
LP-284 has also been granted an Orphan Drug Designation (ODD) by the
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately
Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over
Please find more information at:
- Website: www.lanternpharma.com
- LinkedIn: https://www.linkedin.com/company/lanternpharma/
- X: @lanternpharma
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that promising observations in preclinical studies do not ensure that later studies and development will be successful, (iii) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612787863/en/
Investor Relations
mailto: ir@lanternpharma.com
ph: (972) 277-1136
Source: Lantern Pharma Inc.
FAQ
What is Lantern Pharma's drug candidate LP-284?
What recent milestone did Lantern Pharma achieve for LP-284?
Which countries have issued patents for LP-284?
What is the potential market size for LP-284?
What is the status of LP-284's clinical trials?
How many patients could LP-284 potentially benefit annually?
What designations has LP-284 received from the U.S. FDA?
